ArticleClinical rheumatology2026
Time to first recurrent thrombosis in adults with thrombotic antiphospholipid syndrome: a registry-based retrospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate time to first recurrent thrombosis and to explore the association between recurrent thrombosis and clinical, laboratory/immunological, and treatment-related factors among Colombian adults with thrombotic antiphospholipid syndrome (APS) enrolled in the ARTMEDICA autoimmune diseases program (2013-2024).
methodsWe conducted a registry-based retrospective follow-up study of patients with thrombotic APS. Patients were followed from the index thrombotic event to the first recurrent arterial or venous thrombosis. Time-to-event analyses used interval-censored parametric survival regression with a log-logistic distribution. To explore factors associated with recurrence, we also applied a matched nested case-control design using conditional logistic regression.
resultsWe included 355 patients (mean follow-up 6.6 years), 71.0% female, median age 47 years (IQR 32-60). Primary APS accounted for 83.4% of cases, and the index event was arterial in 72.1%. During follow-up, 130 patients experienced a first thrombotic recurrence: 70.8% venous. The 10-year probability of first recurrence was 42% (95% CI 28.4-55.5%), with 20% (95% CI 10.5-29.1%) during the first 2 years. In the nested case-control, recurrent thrombosis was significantly associated with the LA + /aCL + /antiβ2GPI - profile (OR 4.8; p = 0.044), male sex (OR 1.8; p = 0.038), prior gestational death (OR 2.4; p = 0.008), and ANA positivity (OR 2.4; p = 0.015).
conclusionsThe risk of recurrent thrombosis was highest during the first 2 years after the index thrombotic event, supporting an early vulnerable phase and underscoring the need for closer clinical surveillance and secondary prevention. Limitations of the study include its retrospective design, the lack of standardized anticoagulation monitoring and residual confounding. Key Points • Thrombotic APS carries a high early recurrence burden despite anticoagulation, particularly during the first 2 years after the index event. • Early identification of high-risk patients and intensive surveillance may be critical to prevent recurrent thrombosis.
Indexed as
Identifiers
42706480What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.